Bionpharma Drug Patent Portfolio
Bionpharma owns 2 orange book drugs protected by 6 US patents Given below is the list of Bionpharma's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10022344 | Liquid dosage forms of sodium naproxen | 03 Mar, 2026 | Active |
US10028925 | Liquid dosage forms of sodium naproxen | 03 Mar, 2026 | Active |
US11090280 | Liquid dosage forms of sodium naproxen | 03 Mar, 2026 | Active |
US9693978 | Solvent system for enhancing the solubility of pharmaceutical agents | 03 Mar, 2026 | Active |
US9693979 | Liquid dosage forms of sodium naproxen | 03 Mar, 2026 | Active |
US6251426 | Ibuprofen-containing softgels | 25 Jun, 2018 | Expired |
Latest Legal Activities on Bionpharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bionpharma.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 4th Year, Large Entity | 12 Jan, 2022 | US10028925 |
Payment of Maintenance Fee, 4th Year, Large Entity | 05 Jan, 2022 | US10022344 |
Patent Issue Date Used in PTA Calculation
Critical
| 17 Aug, 2021 | US11090280 |
Recordation of Patent Grant Mailed
Critical
| 17 Aug, 2021 | US11090280 |
Email Notification
Critical
| 29 Jul, 2021 | US11090280 |
Issue Notification Mailed
Critical
| 28 Jul, 2021 | US11090280 |
Application Is Considered Ready for Issue
Critical
| 22 Jul, 2021 | US11090280 |
Dispatch to FDC | 22 Jul, 2021 | US11090280 |
Response to Reasons for Allowance | 13 Jul, 2021 | US11090280 |
Issue Fee Payment Verified
Critical
| 13 Jul, 2021 | US11090280 |
Issue Fee Payment Received
Critical
| 13 Jul, 2021 | US11090280 |
Email Notification
Critical
| 30 Jun, 2021 | US11090280 |
Mail Notice of Allowance
Critical
| 30 Jun, 2021 | US11090280 |
Electronic Review
Critical
| 30 Jun, 2021 | US11090280 |
Notice of Allowance Data Verification Completed
Critical
| 27 Jun, 2021 | US11090280 |
Bionpharma's Drug Patent Litigations
Bionpharma's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 14, 2018, against patent number US9693979. The petitioner Catalent Pharma Solutions, Inc., challenged the validity of this patent, with Patheon Softgels Inc. as the respondent. Click below to track the latest information on how companies are challenging Bionpharma's patents.
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
US11090280 | July, 2020 |
Decision
(24 May, 2021)
| PATHEON SOFTGELS INC | |
US9693978 | January, 2018 |
Terminated-Denied
(13 Aug, 2018)
| Patheon Softgels Inc. | Catalent Pharma Solutions, Inc. |
US9693979 | January, 2018 |
Terminated-Denied
(13 Aug, 2018)
| Patheon Softgels Inc. | Catalent Pharma Solutions, Inc. |
Bionpharma Drug Patents' Oppositions Filed in EPO
Bionpharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 14, 2017, by Dieckhoff, Beate. This opposition was filed on patent number EP06737018A. Click below to reveal the latest opposition data.
Application | Filing Date | Opposition Party | Legal Status |
---|---|---|---|
EP06737018A | Jun, 2017 | Dieckhoff, Beate | Patent maintained as amended |
Bionpharma's Family Patents
Bionpharma Drug List
Given below is the complete list of Bionpharma's drugs and the patents protecting them.
1. Midol Liquid Gels
Midol Liquid Gels is protected by 1 patent, which has expired already. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6251426 | Ibuprofen-containing softgels |
25 Jun, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Midol Liquid Gels's drug page
2. Naproxen Sodium
Naproxen Sodium is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10022344 | Liquid dosage forms of sodium naproxen |
03 Mar, 2026
(1 year, 4 months from now)
| Active |
US10028925 | Liquid dosage forms of sodium naproxen |
03 Mar, 2026
(1 year, 4 months from now)
| Active |
US11090280 | Liquid dosage forms of sodium naproxen |
03 Mar, 2026
(1 year, 4 months from now)
| Active |
US9693978 | Solvent system for enhancing the solubility of pharmaceutical agents |
03 Mar, 2026
(1 year, 4 months from now)
| Active |
US9693979 | Liquid dosage forms of sodium naproxen |
03 Mar, 2026
(1 year, 4 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Naproxen Sodium's drug page